WuXi STA signs exclusive technology and marketing partnership with BioLingus
Singapore, Feb. 19 -- STA Pharmaceutical Co., Ltd., (WuXi STA), a subsidiary of WuXi AppTec, and BioLingus, a Swiss biotech company, have formed an exclusive technology and marketing collaboration for sublingual delivery.
Under the terms of the collaboration, WuXi STA will have exclusive access to BioLingus technology for sublingual and buccal delivery in the contract development and manufacturing organization (CDMO) sector. BioLingus has developed a novel platform - with patents secured in major countries around the world - to stabilize and deliver sublingually (orally under the tongue) drug targets including small molecules, peptides and proteins that are currently administered to patients via injection.
The collaboration will help fu...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.